Delpor Appoints Jay Smith as Chief Commercial Officer to Lead Commercialization of Once-Yearly Risperidone Implant
Smith will also be responsible for optimizing customer experience for Delpor’s implant products, as he oversaw over 23k procedures for another implant biotech BRISBANE, CA, March 31, 2021 — Delpor, [...]
Delpor to Tackle Opioid Use Disorder with $5.7 million NIH HEAL Grant Award for the Development of a Once-Yearly Naltrexone Therapy to Prevent Relapses
Company to expand the use of its PROZOR implant technology by building on the success with its lead antipsychotic program Upon successful completion of the grant’s initial phase, Delpor may [...]
Delpor Awarded $1.5 million NIH Grant for Exenatide Implant for the Treatment of Type 2 Diabetes
The NIDDK continues to fund Delpor’s efforts to utilize its NANOPORTM technology in developing a matchstick-size subcutaneous implant device capable of delivering exenatide for 3-12 months through passive diffusion SAN FRANCISCO, [...]
Delpor Announces Issuance of US Patent Covering its Novel Implantable Device for the Long-Term Delivery of Antipsychotics and other Drugs
The patent covers Delpor’s PROZORTM technology which enables the sustained release of antipsychotics and other molecules from a matchstick-size implant device. Delpor has several products in development, including a 6-month formulation [...]
Delpor Selected by the NIH to Exhibit its Technology at the 2017 BIO International Convention
Delpor will be part of the Innovation Zone, a high profile 6,000 square foot exhibit space dedicated to showcasing 60 NIH and 20 NSF SBIR/STTR awardees. Delpor expects to meet [...]
Delpor Awarded NIH Grant for 3-month Olanzapine Implant for the treatment of Schizophrenia
The NIMH funds Delpor’s efforts to utilize its PROZORTM technology in developing a matchstick-size subcutaneous implant device capable of delivering olanzapine for 3 months through passive diffusion. The product is expected [...]
Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device
Delpor has exclusive rights to the patented technology and has several product candidates in development, including 3-6 month formulations of exenatide, liraglutide, and basal insulin. SAN FRANCISCO, CA, April 23, [...]
Delpor Awarded $220K NIH Grant for 3-month Exenatide Implant for the Treatment of Type 2 Diabetes
The NIDDK funds Delpor’s efforts to utilize its NANOPORTM technology in developing a matchstick-size subcutaneous implant device capable of delivering exenatide for 3-12 months through passive diffusion SAN FRANCISCO, CA, Oct [...]
Delpor Awarded $340K NIH Grant for 3-month Long Acting Risperidone Product in order to Improve Medication Adherence in Schizophrenia and Bipolar Disorder
Delpor’s innovative Prozor technology receives support from the National Institute of Mental Health in an effort to reduce relapse in patients suffering from schizophrenia and bipolar disorder. SAN FRANCISCO, CA, [...]
Ernest Mario Joins the Board of Delpor, Inc.
Delpor continues to strengthen its expertise in drug delivery with the addition of the former CEO of Glaxo and Alza to its Board of Directors. SAN FRANCISCO, CA, January 19, [...]
Delpor, Inc. Announces Scientific Advisory Board with Experts in Psychiatry and Drug Delivery
Panel of internationally renowned researchers and clinicians will guide development of Delpor’s drug delivery based products in schizophrenia, hepatitis C, diabetes, and other diseases. SAN FRANCISCO, CA, July 13, 2011 [...]
Delpor, Inc. Announces Issuance of Nanopore Drug Delivery Patent
Nanopore technology enables the sustained release of drugs during several months from a small subcutaneous implant device. SAN FRANCISCO, CA, June 23, 2011 – Delpor, Inc. (Delpor), a biotechnology company [...]